Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
IPO Year: 2019
Exchange: NYSE
Website: avantorsciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | $14.00 | Buy → Neutral | Goldman |
| 4/28/2025 | $15.50 | Buy → Hold | TD Cowen |
| 4/28/2025 | $14.00 | Buy → Hold | Stifel |
| 4/28/2025 | Overweight → Equal-Weight | Morgan Stanley | |
| 1/17/2025 | $29.00 → $25.00 | Buy → Neutral | UBS |
| 8/28/2024 | $30.00 | Overweight | Wells Fargo |
| 7/10/2024 | $30.00 → $23.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $19.50 → $26.00 | In-line → Outperform | Evercore ISI |
| 12/11/2023 | $21.00 → $28.00 | Market Perform → Outperform | TD Cowen |
| 9/28/2023 | $22.00 | Mkt Perform | Bernstein |
RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience
Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led
Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q
Industry leading set of technologies to drive scalability, flexibility, and efficiency in biologics production RADNOR, Pa., April 1, 2025 /PRNewswire/ -- Avantor®, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, announces its presence at INTERPHEX, the premier annual gathering of pharmaceutical, biotechnology, and device development and manufacturing professionals. The company will showcase fluid handling technologies that support every step of the bioprocessing continuum, delivering exceptional scalability, flexibility, and efficiency in media and buffer preparation, filtration, purification, and final form
RADNOR, Pa., March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl
Facility in Gliwice, Poland to boost biopharma manufacturers' efficiency and speed to market of therapies RADNOR, Pa., March 17, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services in the life sciences and advanced technology industries, announces that Ger Brophy, PhD, head of Avantor's Scientific Advisory Board, will present highlights of the recently completed expansion at its flagship European manufacturing site at Drug, Chemical & Associated Technologies Association (DCAT) Week 2025. Dr. Brophy's presentation will take place as part of the Member Company Announcement Forum on Monday, March 17, at approximately 9:15 am easter
RADNOR, Pa., Feb. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will present at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, at 11:50 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days
Silq Technologies Corporation, a privately held advanced materials science company, and NuSil Technology LLC, a subsidiary of Avantor Inc., Radnor, Pa. (NYSE:AVTR), and a leading global supplier of high-quality silicones for long-term medical implants, have entered into an agreement to facilitate the utilization of Silq's zwitterionic surface treatment technology on medical devices manufactured with NuSil silicone products. Zwitterion surface technology has been a major subject of research in academia for several decades because of its potential to reduce medical implant-associated infections and complications without the use of antibiotics. Zwitterion functionalized surfaces have also bee
Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1%Net income of $500.4 million; Adjusted EBITDA of $307.7 millionDiluted GAAP EPS of $0.73; adjusted EPS of $0.27Operating cash flow of $173.3 million; free cash flow of $222.1 millionFull Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2%Net income of $711.5 million; Adjusted EBITDA of $1,198.8 millionDiluted GAAP EPS of $1.04; adjusted EPS of $0.99Operating cash flow of $840.8 million; free cash flow of $768.3 millionRADNOR, Pa., Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences
RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 7, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscie
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
8-K - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
10-Q - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
DEFA14A - Avantor, Inc. (0001722482) (Filer)
DEF 14A - Avantor, Inc. (0001722482) (Filer)
SCHEDULE 13G/A - Avantor, Inc. (0001722482) (Subject)
10-K - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00
TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50
Stifel downgraded Avantor from Buy to Hold and set a new price target of $14.00
Morgan Stanley downgraded Avantor from Overweight to Equal-Weight
UBS downgraded Avantor from Buy to Neutral and set a new price target of $25.00 from $29.00 previously
Wells Fargo initiated coverage of Avantor with a rating of Overweight and set a new price target of $30.00
Citigroup downgraded Avantor from Buy to Neutral and set a new price target of $23.00 from $30.00 previously
Evercore ISI upgraded Avantor from In-line to Outperform and set a new price target of $26.00 from $19.50 previously
TD Cowen upgraded Avantor from Market Perform to Outperform and set a new price target of $28.00 from $21.00 previously
Bernstein initiated coverage of Avantor with a rating of Mkt Perform and set a new price target of $22.00
Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led
Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q
RADNOR, Pa., March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl
Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1%Net income of $500.4 million; Adjusted EBITDA of $307.7 millionDiluted GAAP EPS of $0.73; adjusted EPS of $0.27Operating cash flow of $173.3 million; free cash flow of $222.1 millionFull Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2%Net income of $711.5 million; Adjusted EBITDA of $1,198.8 millionDiluted GAAP EPS of $1.04; adjusted EPS of $0.99Operating cash flow of $840.8 million; free cash flow of $768.3 millionRADNOR, Pa., Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences
RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 7, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscie
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7%Net income of $57.8 million; Adjusted EBITDA of $302.5 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.26Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. "Our team delivered another quarter o
RADNOR, Pa., Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2024 financial results before the market opens on Friday, October 25, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global provider of mission
Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to be used for debt paydownRADNOR, Pa., Aug. 16, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the signing of a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively "Clinical Services"), to Audax Private Equity ("Audax") for a transaction value of approximately $650 million. "Today's announcement is an important step fo
Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0%Net income of $93 million; Adjusted EBITDA of $306 millionDiluted GAAP EPS of $0.14; adjusted EPS of $0.25Operating cash flow of $281 million; free cash flow of $235 millionRADNOR, Pa., July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024."Our teams delivered another solid quarter with sequential improvements to all key financial metrics. Improved mix from increased bioprocessing revenue together with t
RADNOR, Pa., June 28, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2024 financial results before the market opens on Friday, July 26, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global prov
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform
Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees
NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS
RADNOR, Pa. , June 21, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Corey Walker has rejoined the company as President of Avantor's Laboratory Solutions business, reporting to CEO Michael Stubblefield. "Corey's deep knowledge of our end markets and industry, coupled with his familiarity with our organization and customers, makes him the ideal leader for our Laboratory Solutions business," said Michael Stubblefield,